Movement Breaks
BehavioralParticipants will be asked to perform 30-60 second movement breaks 3-4 times per day on at least 3 days per week.
Other names: Activity Snacks
NCT Number: NCT05574426
The purpose of this study is to determine the efficacy of performing "exercise snacks" (short movement breaks throughout the day) on various measures of cardiometabolic health.
Looking for future studies?
Notify Me40 year–64 year
All sexes
Interventional
Not applicable
University of British Columbia, Kelowna, British Columbia, Canada
After being informed about the study and potential risks, all eligible participants who have provided consent will undergo a baseline visit to assess pre-intervention basic anthropometrics, cardiorespiratory fitness, and provide a blood sample. Participants will then be randomized in a 1:1 ratio to one of two groups: 1) Mobility movement breaks (stretching or range of motion exercises); or 2) Cardiovascular movement breaks (designed to raise heart rate). Both groups will be encouraged to perform 3-4 daily movement breaks on at least 3 days of the week with support from an online platform and app that provides video instructions and reminders to complete the movement breaks. After 12 weeks, participants will be asked to return to the lab for the same testing performed at baseline.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will be asked to perform 30-60 second movement breaks 3-4 times per day on at least 3 days per week.
Other names: Activity Snacks
Time frame: Baseline and Week 12
Cardiorespiratory fitness will be assessed as the highest 30-s average from a laboratory-based graded VO2peak test on a cycle ergometer.
Time frame: Baseline and 12 weeks
A fasted venous blood sample will be obtained and insulin measured by commercial assay.
Time frame: Baseline and 12 weeks
A fasted venous blood sample will be obtained and glucose measured by biochemical assay.
Time frame: Baseline and 12 weeks
A fasted venous blood sample will be obtained and insulin resistance estimated by homeostasis model assessment (HOMA) score
Time frame: Baseline and 12 weeks
A fasted venous blood sample will be obtained and inflammatory cytokines measured by multiplex assay
Time frame: Baseline and 12 weeks
Body mass will be measured by weigh scale
Time frame: Baseline and 12 weeks
Waist circumference (in centimetres) will be measured using a measurement tape.
Time frame: Week 2 and week 11
Participants will wear accelerometers to assess adherence near the beginning and the end of the intervention.
Time frame: Once per week for 12 weeks
Participants will be sent weekly surveys asking them to recall the total number of movement breaks performed that week.
Time frame: Immediately following each movement break for entire 12-week intervention
The EES is a validated, single-item 7-point scale to assess exercise enjoyment. Possible scores range from 1 (not at all) to 7 (extremely).
Time frame: Immediately following each movement break for entire 12-week intervention
A 10 point RPE scale will be used to assess perceived exertion ranging from 0 (rest) to 10 (maximal).
University of British Columbia
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07398820
Behavior, Colonic Diseases
Las Condes, Santiago Metropolitan, Chile
View Trial DetailsNCT07265869
Ageing, Behavior
Birmingham, West Midlands, United Kingdom
View Trial DetailsNCT04262128
Behavior, Cardiovascular Diseases
Aurora, Colorado, United States
View Trial DetailsNCT04749849
Behavior, Cardiovascular Diseases
Iowa City, Iowa, United States
View Trial Details